Drug Profile
Research programme: SmPill formulated products - Sublimity Therapeutics
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Sigmoid Pharma
- Developer Sublimity Therapeutics
- Class Antidiarrhoeals; Antineoplastics; Nonsteroidal anti-inflammatories; Steroids
- Mechanism of Action Cyclooxygenase inhibitors; Enzyme inhibitors; Immunomodulators; Protein modulators; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coeliac disease; Colorectal cancer; Diarrhoea; Inflammatory bowel diseases
Most Recent Events
- 27 Sep 2023 Preclinical development is ongoing in Coeliac disease in Ireland (PO) (Sigmoid Pharma pipeline; September 2023)
- 27 Sep 2023 Preclinical development is ongoing in Colorectal-cancer in Ireland (PO) (Sigmoid Pharma pipeline; September 2023)
- 27 Sep 2023 Preclinical development is ongoing in Diarrhoea in Ireland (PO) (Sigmoid Pharma pipeline; September 2023)